What factors account for keytruda's higher price?

Keytruda (pembrolizumab) is typically priced high because of a mix of market, clinical, and manufacturing/regulatory factors. Common drivers include:

• It’s a breakthrough, high-value biologic: Keytruda is an immune checkpoint inhibitor used across multiple cancer types. Demand is strong because it can improve outcomes for many patients, including in cancers where options were limited.
• High R&D and clinical trial costs: Developing an oncology biologic takes years and involves very large, expensive trials (often across many indications). Even with success, costs are spread across fewer products.
• Regulatory exclusivity and limited near-term competition: While biosimilars exist for some PD-1 drugs in certain markets, pricing power can remain high when competition is limited, or when biosimilar substitution is slower than for small-molecule drugs.
• Complex manufacturing: As a monoclonal antibody, Keytruda requires sophisticated cell culture, biologics-specific purification, stringent quality testing, and cold-chain logistics—all of which increase cost.
• Intellectual property coverage: Patents and exclusivity around the drug and its formulations/uses can delay generic or biosimilar entry.
• High and variable reimbursement dynamics: In oncology, list prices are often influenced by how payers negotiate discounts and rebates, and by how health systems evaluate cost-effectiveness for different cancer settings.
• Indication expansion over time: As Keytruda gained approvals for more cancers, pricing and contracting often reflect the broader labeled opportunity and sustained demand.

If you tell me your country (US, UK, Canada, etc.) and whether you mean the list price, the out-of-pocket price, or the wholesale acquisition cost, I can explain the most relevant drivers for that specific market.